Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Prices have not been this low since June 2019. Looks like the chart historically bounces off these levels going back to 2009.
Big move coming $AXIM
Added 2469 shares at .405 $AXIM
"Been" ??? It was for one day. Get out of this board dude.
This is supposed to be the hot season too for otc. I wonder if the halts and new reporting requirements put the kaibosh on that.
Bounce coming $GNBT
Bounce coming?
Buying the ask and 20 min later still no fill. Wtf?
Been seeing a lot of tickers fall off a cliff. AGT*, VP*R, DSC*, IPI*, might be a bad season for otc
Oversold, let's bounce
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19
9:00 AM ET 11/16/21 | GlobeNewswire
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19
Company develops COVID-19 "Correlate of Protection" research to measure levels of neutralizing antibodies which protect from infection
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced today that it has partnered with Arizona State University to develop a COVID-19 "Correlate of Protection" using AXIM's rapid neutralizing antibody test.
The collaborative study between AXIM and Arizona State University (ASU) will address this unmet need and determine a threshold for when neutralizing antibody levels have declined so that they no longer protect against infection and potential disease. In this manner, neutralizing antibody levels will be used as a "Correlate of Protection".
Dr. Douglas Lake at ASU will enroll a high-risk population and monitor their neutralizing antibody levels weekly using AXIM's rapid neutralizing antibody test while also testing them weekly for the presence of SARS-CoV-2 by PCR.
Dr. Lake stated, "We expect that people whose neutralizing antibody levels are high will not become infected compared to those that have low levels of neutralizing antibodies. Using this study design, our goal is to develop a 'Correlate of Protection' so that people can keep their antibody levels high enough to avoid infection and potential transmission of the virus to vulnerable populations."
John Huemoeller, CEO of AXIM Biotech added, "When our rapid test indicates that someone's neutralizing antibody levels are low, healthcare providers might recommend a booster dose of COVID-19 vaccine, especially for someone who is high risk such as a healthcare provider, teacher, immunosuppressed or elderly. This study will answer the question on everyone's mind, "How low do my neutralizing antibodies levels need to fall before I am no longer protected from COVID-19 infection?"
Although both antibodies and T cells are involved in protection from COVID-19, anti-viral T cell responses are technically and logistically difficult to measure. Unlike T cells, anti-viral antibodies are relatively easy to detect and measure from a finger-stick drop of blood. AXIM's rapid test is special because it measures levels of neutralizing antibodies which provide protection from infection if blood levels are high enough. The problem is that it is not known what levels of neutralizing antibodies protect from infection.
About AXIM(R) Biotechnologies
Founded in 2014, AXIM(R) Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM's COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED. For more information, please visit www.AXIMBiotech.com.
Looks like a dud.
.4789!
AXIM due for an oversold bounce, let's do this
Press Release: Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidins Potential Inclusion in Government-Sponsored COVID-19 Trials
8:01 AM ET 11/12/21 | Dow Jones
Additionally, new in vitro data also show Brilacidin targets both viral proteins and host factors, suggesting Brilacidin would be less prone to developing resistance compared to other antivirals
WAKEFIELD, MA / ACCESSWIRE / November 12, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the Company is conducting full data analysis of the Phase 2 Brilacidin COVID-19 clinical trial results to support Brilacidin's potential inclusion in government-sponsored COVID-19 trials. The Company also is pleased to announce public release of new in vitro data based on extensive research by scientists at the University of Arizona and the University of California-San Francisco (UCSF), showing that Brilacidin functions as a dual-acting broad-spectrum inhibitor of coronaviruses.
Topline results for the Phase 2 Brilacidin COVID-19 clinical trial (see NCT04784897) have been reported. Complete analysis of trial results already has begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials, such as the U.K.'s CTAP program and the NIH's ACTIV program. The purpose of these programs is to prioritize development of promising COVID-19 therapeutics. Some COVID-19 drug candidates that did not meet their trial's primary endpoint, for example Relief Therapeutics' aviptadil, or those that showed inconclusive results in early clinical testing (e.g., anti-IL-6 drugs), have later gone on to be included in larger platform trials based on deeper analysis of trial results.
The Company's intent, should full analysis of the Brilacidin COVID-19 trial results yield promising data, is to submit Brilacidin for inclusion in these larger COVID-19 platforms. Sufficient intravenous Brilacidin drug supply is on hand to support further clinical testing of Brilacidin in COVID-19.
Highlights of New In Vitro Research
The new Brilacidin scientific findings, accessible as a preprint at the bioRxiv link provided below, are to be submitted for peer-review publication.
-- Yanmei Hu, Hyunil Jo, William DeGrado, Jun Wang. Brilacidin, a COVID-19
Drug Candidate, Demonstrates Broad-Spectrum Antiviral Activity Against
Human Coronaviruses OC43, 229E and NL63 Through Targeting Both the Virus
and the Host Cell. bioRxiv 2021.11.04.467344; doi:
https://doi.org/10.1101/2021.11.04.467344https://www.biorxiv.org/content/10.1101/2021.11.04.467344v1.full
Let the dust settle I guess. I've been in tickers where the drug did not pass FDA clearance, but down 80% is unwarranted in my opinion. At 80% red, I think most of us can get out at 40% red soon enough. I can't remember a ticker going down 80% and staying down or going lower immediately after. Check out VP*R for example. Traded at .009s, 60% drop to 004, now trading at 0072 a month later.
idk, looks pretty finished to me.
I'm guessing next week.
Let's break out of these levels $PJET
Not liking the bid at .0093 right now.
News!!! Let's bounce!!
It's always next week. Still nothing here.
Let's bounce $AXIM
Thanks pal
May I ask where I can find this info?
Let's break 0.6
12 days red, 13th green.
I dumped at .014 for a 25% loss then averaged at .0093 for a recoup play. I'm starting to wonder if .0093 is still too high.
Dear MA200 at .0075, please save this!
.0085's bidding. Wow, we're really going to make it 12 red days in a row. I can't remember the last time I've witnessed something like this.
Long lower wick on the hourly. If it doesn't bounce tomorrow, it doesn't bounce at all.
It's absurd.
This will not bounce.
Need a bounce here
My buy orders at .41/.42 filled today. This may go much lower, but I doubt that it will do that without a good bounce. 2 reasons:
1. RSI is very low, at 26.90. The daily RSI has not been this low since early 2020, when it bounced 400% 2 months after.
2. The monthly Kaufman's moving average is currently at 0.40. Pps may dip lower, but I believe a very good bounce from here will happen simply for technical/charting reasons.
Yeh... I have $ here that I'm willing to send down with the ship, but I sure hope she bounces hard off the 0.4 area $AXIM
Bullish engulfing
That's not a good candle today
Bought some here, oversold. Bounce coming $AXIM